Loading...
Market
Summit Therapeutics' drug achieves $1 billion in sales by end of 2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Summit Therapeutics' financial reports
Story
Summit Therapeutics' Cancer Drug Outperforms Keytruda in China Study; Shares Up 227%
May 30, 2024, 10:06 PM
Summit Therapeutics' experimental cancer drug has outperformed Merck's Keytruda in a Phase 3 lung cancer study conducted in China. The study, which focused on non-small cell lung cancer (NSCLC), showed that Summit's drug, developed in partnership with Akeso, met its primary endpoint of progression-free survival (PFS). This result led to a significant surge in Summit's shares, which rose by 227%, bringing its market cap to $5 billion. Despite the positive outcome, there are concerns about the study's relevance outside China, as the FDA does not recognize Chinese clinical trial data. The drug, which targets both PD-1 and VEGF, may require further comparative studies against Keytruda combined with chemotherapy to validate its efficacy. Bob Duggan's small biotech company has garnered significant attention with this bispecific drug.
View original story
Similar markets
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Less than 500 million USD • 25%
500 million - 1 billion USD • 25%
1 billion - 2 billion USD • 25%
More than 2 billion USD • 25%
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Only in China • 25%
In China and one other major market (e.g., US or EU) • 25%
In China and multiple other major markets • 25%
In no major markets • 25%
Yes • 50%
No • 50%
FDA approval application • 25%
Partnership with another company • 25%
Further clinical trials • 25%
No significant action • 25%